Bharat joined Catamaran as Senior Director of Business Development in March 2020. Prior to Catamaran, Bharat was a consultant to SV Health Investors. In his previous role, he was a Director of Business Development at bluebird bio, a biotech focused on developing cell and gene therapies for both severe genetic diseases and oncology applications. In his role at bluebird, Bharat was instrumental in executing and managing multiple key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with Regeneron, Gritstone Oncology, Fred Hutchinson Cancer Research Center, and Seattle Children’s Research Institute. Prior to his role at bluebird, Bharat was a consultant at ClearView Healthcare Partners where he worked with clients in the life science industry to develop commercialization strategies and support new product planning efforts. Bharat holds a PhD from the Department of Biological Sciences at Columbia University and a BA from Bowdoin College.
Celeste joined Catamaran as Senior Vice President, Research, in June 2020. She brings more than 16 years of experience in research and drug discovery in biotech and large pharma. Prior to Catamaran, Celeste served as Vice President of Cell Therapy at Obsidian Therapeutics where she led research strategy and execution through successful transition from seed funding through Series A to pharma partnership and internal pipeline build. Prior to Obsidian, Celeste served as a Research leader in Oncology and Immuno-Oncology at Novartis for 12 years, driving programs in Cell Therapy and Biologics spanning target discovery through IND submission. Celeste conducted her postdoctoral training at Harvard Medical School, where she studied cancer cell signaling. Celeste holds a PhD in Biochemistry and Molecular Biology from the University of Chicago and a BA in Biology from Carleton College.
Chris joined Catamaran as Chief Medical Officer in November 2020. He brings more than two decades of clinical and laboratory experience in oncology. Prior to Catamaran, Chris was Chief Medical Officer of Rubius Therapeutics. Previously, Chris was a Senior Vice President and Head of the Cancer Epigenetics Discovery Performance Unit at GlaxoSmithKline. He was responsible for the overall strategy, as well as the identification and validation of new targets and advancing novel therapies through clinical proof of concept. Under his leadership the group brought four compounds into clinical development. While at GSK, Chris also led the clinical development of Votrient® (pazopanib). Prior to GSK, he led the clinical development of MK-4827, which became Tesaro’s Zejula®. Prior to Merck, Chris led a laboratory focus on signal transduction at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in medical oncology. Chris holds a BS from Stanford University and MD and PhD (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.
Mark joined Catamaran as Chief Operating Officer in March 2020. He brings more than twenty-five years of experience in the biotechnology industry—spanning operations, legal affairs and busines development. Most recently, he served as Vice President, Legal Affairs of Rubius Therapeutics where he founded and built the legal department and led all internal legal activities supporting Rubius’ rapid growth to a clinical-stage, cell therapy company and its IPO. Prior to Rubius, Mark served as a business and legal advisor to several early-stage, venture-backed biotechnology companies, including senior roles at cell therapy and gene therapy companies. Previously in his career, he served as Associate General Counsel of Millennium Pharmaceuticals (now Takeda Oncology) where he founded and built the legal department and led internal legal activities, including playing instrumental roles in negotiating several major pharmaceutical partnerships and executing the company’s IPO. Prior to Millennium, Mark was Chief Patent Counsel for Repligen Corporation. He began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Mark holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University.
Vipin joined Catamaran as Chief Scientific Officer in March 2020. Along with his deep expertise in researching and developing cell therapies for cancer, Vipin has over two decades of experience in the biotech and pharmaceutical industry. Most recently, he co-founded and led Discovery Research at Obsidian Therapeutics. Vipin’s work at Obsidian led to the development of Obsidian’s cytoDRive platform, which broadened the therapeutic reach of cell and gene therapies. Prior to Obsidian, Vipin was a member of the founding team and Head of Biology at Serien (formerly Raze) Therapeutics and an Entrepreneur in Residence at Atlas Venture. At Raze, Vipin’s research was focused on discovering novel anticancer agents by targeting unique vulnerabilities of rapidly growing tumors. Earlier in his career, Vipin spent more than a decade working in the pharmaceutical industry at GSK, Pfizer, and Wyeth, where his research spanned novel small molecule, peptide, nucleic acid, and protein therapeutics across a wide range of therapeutic areas. Vipin holds a PhD in biochemistry from Brandeis University and an MBA from Yale School of Management.